Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXP-106 in Advanced Solid Tumors
NCT07532018Phase 1Recruiting
- Sponsor
- Singlomics
- Start
- Mar 2026
- Primary completion
- Feb 2028
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DXP-106 in solid tumor, sponsored by Singlomics. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Adverse Events and Serious Adverse Events at 13 months. Started Mar 2026; status: recruiting.
02
Drugs
DXP-106
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07532018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532018.